With the U.S. election behind us, the soaring costs of U.S. healthcare have become a priority for politicians—in particular, the cost of prescription drugs. Some proposed solutions involve external reference pricing from comparable countries and limiting drug price increases. These anticipated changes in U.S. pricing policy, coupled with the downward pressure on drug budgets due to the COVID-19 pandemic, suggest that pharma companies must think globally when setting launch prices.
In this webinar, Ed Corbett and Alan Crowther discuss key challenges that can impact U.S. drug pricing and recommendations to address them, such as evaluating product portfolios and analogue pricing. The latest trends in global pricing practices will be highlighted, as well as the different factors that influence pricing strategies in various markets.
Fill the form below to watch the full webinar:
General Manager, Global Pricing, Access and Digital Solutions
Alan has spent close to 20 years doing commercial work for the life sciences industry. His experience includes creating innovative solutions for global pricing and access, including work on price optimization, global data collection and analysis, and the use of advanced algorithms to support commercial decisions, including pricing.
Head of EMEA,
As the lead for EVERSANA’s EMEA management consulting practice, Ed specializes in commercial and corporate strategy and has significant national and global launch experience. He has helped a diverse set of clients from big pharma to biotech solve a wide range of challenges, including US entry strategy, EU launch excellence, due diligence, and portfolio optimization. […]